Larrea Tridentata Leaf

Dosage for Larrea Tridentata Leaf extract is highly individualized and is not based on a standard 'one-size-fits-all' milligram amount. Instead, it is determined by the patient's level of sensitivity and the specific clinical objective.

Diagnostic Testing

• Prick/Puncture Test: A single drop of the concentrated extract (e.g., 1:20 w/v) is applied to the skin, and the skin is pricked through the drop. The reaction is read after 15 to 20 minutes.
• Intradermal Test: If the prick test is negative but clinical suspicion remains high, a healthcare provider may inject 0.02 to 0.05 mL of a highly diluted extract (e.g., 1:1000 w/v) into the intradermal layer of the skin.

Immunotherapy (Allergy Shots)

• Buildup Phase: Treatment usually begins with a very low dose (e.g., 0.05 mL of a 1:10,000 w/v dilution). The dose is increased weekly or bi-weekly as tolerated by the patient.
• Maintenance Phase: Once the 'top dose' or maintenance dose is reached (often 0.5 mL of a 1:20 or 1:100 w/v concentration), the interval between injections is increased to every 2 to 4 weeks.

Larrea Tridentata Leaf extract may be used in children, but the dosage must be approached with extreme caution.

• Diagnostic Testing: Similar to adults, though the number of skin tests performed at one time may be limited to avoid excessive discomfort or systemic absorption.
• Immunotherapy: Dosing is generally similar to adult protocols, but the rate of dose escalation may be slower. Children should be closely monitored for systemic reactions, as they may have more difficulty communicating early symptoms of anaphylaxis.

Renal Impairment

No specific dosage adjustments are required for patients with renal impairment when using Larrea Tridentata Leaf for skin testing. However, if a systemic reaction occurs, the clearance of emergency medications (like epinephrine) may be a consideration in patients with severe kidney disease.

Hepatic Impairment

While the extract itself does not require specific adjustment for liver disease, patients with significant hepatic impairment should be monitored closely if they are also taking other medications that could interact with the immunological response or the treatment of anaphylaxis.

Elderly Patients

Elderly patients may have reduced skin reactivity, leading to potential false-negative results in diagnostic testing. Furthermore, the risk-benefit ratio for immunotherapy must be carefully weighed in older adults with pre-existing cardiovascular disease, as they may be less able to tolerate the physiological stress of a systemic reaction or the administration of epinephrine.

Larrea Tridentata Leaf extract is never for self-administration at home. It must be administered by a trained healthcare professional (usually an allergist or immunologist).

• Skin Testing: The skin (usually the forearm or back) is cleaned with alcohol. The extract is applied, and the provider monitors for a wheal-and-flare response.
• Immunotherapy: The injection is given subcutaneously (under the skin) in the upper arm.
• Post-Injection Observation: Patients must remain in the doctor's office for at least 30 minutes after any injection to be monitored for signs of a systemic allergic reaction.
• Storage: Extracts must be stored in a refrigerator at 2°C to 8°C (36°F to 46°F). They should not be frozen.

If a maintenance immunotherapy dose is missed, the next dose may need to be reduced depending on how much time has passed.

• 1-2 weeks late: The usual dose may often be given.
• 3-4 weeks late: The dose is typically reduced to the previous tolerated level.
• Over 4 weeks late: The buildup process may need to be partially restarted.

An 'overdose' in the context of allergenic extracts usually refers to an injection of a concentration that is too high for the patient's current level of tolerance.

• Symptoms: Rapid onset of hives, swelling (angioedema), wheezing, shortness of breath, drop in blood pressure, and loss of consciousness.
• Emergency Measures: Immediate administration of epinephrine (adrenaline), oxygen, intravenous fluids, and antihistamines. Emergency medical services (911) must be contacted immediately if a reaction occurs outside a clinical setting.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance.

The most common side effects of Larrea Tridentata Leaf extract are localized to the site of administration. These are often expected as part of the diagnostic process.

• Local Wheal and Flare: A raised, itchy bump at the test site. This typically appears within 15 minutes and resolves within a few hours.
• Local Swelling: During immunotherapy, it is common to experience swelling at the injection site (up to the size of a half-dollar). This may feel warm or tender.
• Pruritus (Itching): Intense itching at the site of the skin test or injection.

• Large Local Reactions: Swelling that exceeds 5-10 cm in diameter at the injection site. This may persist for 24 to 48 hours.
• Fatigue: Some patients report feeling unusually tired for several hours after an immunotherapy injection.
• Headache: A mild to moderate headache may occur following treatment.
• Nasal Congestion: A mild 'flare' of allergy symptoms, such as sneezing or a runny nose.

• Urticaria (Hives): Hives appearing on parts of the body away from the injection site.
• Lymphadenopathy: Swelling of the lymph nodes near the injection site (e.g., in the armpit).
• Persistent Granuloma: A small, hard knot under the skin at the injection site that may take weeks to resolve.

> Warning: Stop taking Larrea Tridentata Leaf and call your doctor immediately if you experience any of these.

• Anaphylaxis: A life-threatening, multi-system allergic reaction. Symptoms include a feeling of doom, rapid pulse, and a sharp drop in blood pressure.
• Bronchospasm: Severe wheezing, chest tightness, or difficulty breathing (asthma attack).
• Angioedema: Significant swelling of the face, lips, tongue, or throat, which can obstruct the airway.
• Hypotension: Dizziness, fainting, or lightheadedness caused by low blood pressure.
• Generalized Seizures: Extremely rare, usually associated with severe hypoxia during anaphylaxis.

When used as an allergenic extract, there are few documented long-term side effects. However, it is vital to note the historical context of Larrea Tridentata (Chaparral) ingestion. Long-term oral use of the leaf has been linked to:

• Hepatotoxicity: Chronic liver inflammation, cholestatic jaundice, and in severe cases, fulminant hepatic failure requiring a liver transplant.
• Nephrotoxicity: There have been isolated reports of kidney damage associated with long-term oral supplement use.
• Contact Dermatitis: Repeated topical exposure to the leaf or its resins can lead to chronic skin sensitization and allergic contact dermatitis.

While the FDA does not always apply a traditional 'Black Box' to every individual plant extract, all allergenic extracts carry a general class warning regarding the risk of Severe Systemic Reactions.

• Summary: Larrea Tridentata Leaf extract can cause severe, life-threatening systemic reactions, including anaphylaxis. It should only be administered by healthcare professionals prepared to manage such reactions. Patients with unstable asthma are at a higher risk for fatal outcomes. Always observe the patient for at least 30 minutes post-administration.

Report any unusual symptoms to your healthcare provider.

Larrea Tridentata Leaf extract is a potent biological substance. Its use is restricted to diagnostic and therapeutic purposes under the direct supervision of a physician. It is not a consumer product. Patients must be informed that while the extract is intended to help manage allergies, it can itself trigger a severe allergic reaction.

No specific FDA black box warning exists solely for Larrea Tridentata Leaf; however, it falls under the mandatory class labeling for Allergenic Extracts. This labeling warns that these products can cause severe anaphylaxis. It further states that the risk is increased in patients with severe or poorly controlled asthma and that the extract must be administered in a facility equipped with emergency equipment and medications, including epinephrine.

• Anaphylaxis Risk: This is the most significant risk. Reactions can occur within minutes. Patients must be screened for factors that increase the risk of a severe reaction, such as current illness or high allergen exposure in the environment.
• Asthma Status: Patients experiencing an asthma exacerbation should not receive Larrea Tridentata Leaf injections until their asthma is stable. Fatalities from immunotherapy are most common in patients with poorly controlled asthma.
• Hepatotoxicity (Oral Warning): Although the extract is injected or applied to the skin, patients should be warned against the oral consumption of Larrea Tridentata (Chaparral) leaves or teas, as this can cause severe liver injury.
• Cardiovascular Disease: Patients with significant heart disease may be at higher risk of complications if they experience a systemic reaction or if they require large doses of epinephrine, which can strain the heart.

• Observation Period: A mandatory 30-minute wait in the clinic after every injection.
• Peak Flow Monitoring: For asthmatic patients, a peak flow meter may be used to ensure lung function is stable before administration.
• Liver Function Tests (LFTs): While not standard for the extract, if a patient is known to be consuming Larrea Tridentata orally as a supplement, LFTs (ALT, AST, Bilirubin) should be monitored immediately.

Generally, Larrea Tridentata Leaf does not affect the ability to drive. However, if a patient experiences a systemic reaction or receives antihistamines/epinephrine for a reaction, they should not drive or operate machinery until they have fully recovered and the effects of the emergency medications have worn off.

Alcohol should be avoided on the day of an immunotherapy injection. Alcohol can cause vasodilation (widening of blood vessels), which may increase the rate of allergen absorption and potentially increase the risk or severity of a systemic reaction.

Immunotherapy with Larrea Tridentata Leaf is typically a 3-to-5-year commitment. Stopping treatment prematurely may result in the return of allergy symptoms. There is no 'withdrawal syndrome' associated with discontinuing allergenic extracts, but the desensitization effect will gradually fade over time.

> Important: Discuss all your medical conditions with your healthcare provider before starting Larrea Tridentata Leaf.

• Beta-Blockers (e.g., Propranolol, Atenolol): These medications are contraindicated in patients receiving Larrea Tridentata Leaf immunotherapy. Beta-blockers can make a systemic allergic reaction (anaphylaxis) much more severe and, more importantly, can make the patient resistant to the effects of epinephrine, the primary treatment for anaphylaxis.

• ACE Inhibitors (e.g., Lisinopril): Some evidence suggests that patients on ACE inhibitors may be at an increased risk for more severe systemic reactions to allergenic extracts.
• Tricyclic Antidepressants (TCAs): Medications like amitriptyline have potent antihistamine properties. They can suppress skin test results, leading to false negatives, and may interfere with the body's response to emergency medications.
• MAO Inhibitors: These can potentiate the effects of epinephrine used to treat a reaction, potentially causing a dangerous spike in blood pressure.

• Antihistamines (H1 Blockers): Drugs like cetirizine, loratadine, and diphenhydramine MUST be stopped several days (usually 3-7 days) before skin testing, as they will block the wheal-and-flare response and make the test uninterpretable.
• H2 Blockers (e.g., Famotidine): While less potent than H1 blockers, they can also partially suppress skin reactivity and should be discontinued before diagnostic testing.
• Systemic Corticosteroids: Long-term use of oral steroids (like prednisone) can suppress the immune response and potentially alter the results of skin testing or the efficacy of immunotherapy.

• High-Fat Meals: There is no direct interaction with food for the extract; however, heavy meals and exercise should be avoided immediately before and after an injection to prevent rapid changes in blood flow that could affect allergen absorption.
• Caffeine: Excessive caffeine may increase heart rate, which could complicate the monitoring of a patient's vital signs during an allergic reaction.

• St. John's Wort: May affect the metabolism of various compounds, though its interaction with allergenic proteins is likely minimal.
• Chaparral Supplements: Patients should not take oral Chaparral supplements while receiving Larrea Tridentata Leaf extracts, as this increases the risk of hepatotoxicity and may confuse the clinical picture of any adverse reactions.

• Skin Tests: As noted, antihistamines and certain antidepressants will cause false-negative skin test results.
• Serum IgE Tests: The administration of Larrea Tridentata Leaf extract may cause a transient increase in total serum IgE levels, which could interfere with the interpretation of other allergy blood tests.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.

Larrea Tridentata Leaf extract must NEVER be used in the following circumstances:

• Severe, Uncontrolled Asthma: Patients with a Forced Expiratory Volume in 1 second (FEV1) consistently below 70% of predicted values or those with recent frequent exacerbations are at an unacceptably high risk of fatal anaphylaxis.
• Recent Myocardial Infarction (Heart Attack): Within the last 3-6 months. The heart cannot tolerate the potential stress of a systemic reaction or the emergency use of epinephrine.
• Beta-Blocker Therapy: Due to the inability to effectively treat anaphylaxis with epinephrine.
• Known Hypersensitivity to Diluent Ingredients: Such as phenol (used as a preservative) or glycerin.

Healthcare providers must perform a careful risk-benefit analysis in these cases:

• Autoimmune Diseases: There is a theoretical risk that immunotherapy could exacerbate certain autoimmune conditions by stimulating the immune system.
• Malignancy: Patients with active cancer may have altered immune responses.
• Pregnancy (Initiation): Immunotherapy should generally not be started during pregnancy due to the risk of anaphylaxis-induced fetal hypoxia (lack of oxygen to the baby).
• Severe Atopic Dermatitis: May make the interpretation of skin tests difficult due to baseline skin inflammation.

Patients who are allergic to other members of the Zygophyllaceae family may show cross-reactivity with Larrea Tridentata Leaf extract. Additionally, patients with known sensitivities to certain desert plants (like Sagebrush or Ragweed) should be tested carefully, as they may have a lower threshold for systemic reactions when multiple allergens are introduced.

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Larrea Tridentata Leaf.

Larrea Tridentata Leaf extract is generally classified as Pregnancy Category C.

• Risk Summary: There are no adequate and well-controlled studies in pregnant women. The primary danger during pregnancy is not the extract itself, but the risk of a systemic allergic reaction (anaphylaxis) in the mother. Anaphylaxis can lead to maternal hypotension and uterine hypoperfusion, resulting in fetal distress, preterm labor, or fetal death.
• Clinical Considerations: Most allergists recommend continuing maintenance immunotherapy during pregnancy if the patient is already at a stable dose and tolerating it well. However, increasing the dose (buildup phase) is typically avoided until after delivery.

It is not known whether the components of Larrea Tridentata Leaf extract are excreted in human milk. Because the allergenic proteins are large molecules and are administered in very small quantities, significant passage into breast milk is unlikely. The risk to the nursing infant is considered low, but the mother should be monitored for any systemic reactions that could interfere with breastfeeding.

Larrea Tridentata Leaf extract is used in children, but safety and efficacy have not been established for infants under the age of 5.

• Growth Effects: There is no evidence that allergenic extracts affect growth or development.
• Considerations: Children may be more prone to large local reactions. The emotional stress of frequent injections should also be considered in the treatment plan.

Clinical studies of Larrea Tridentata Leaf extract did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently than younger subjects.

• Risks: Older adults are more likely to have co-morbidities like coronary artery disease or COPD, which increase the danger of anaphylaxis.
• PK Changes: Age-related thinning of the skin may affect the accuracy of intradermal testing.

No dosage adjustment is typically required. However, the patient's overall health and ability to tolerate emergency treatment for anaphylaxis must be assessed if they have end-stage renal disease (ESRD).

While the extract is not known to be hepatotoxic when used as directed (injection/skin test), patients with pre-existing liver disease should be cautioned against using any oral forms of Chaparral, which could cause further liver injury.

> Important: Special populations require individualized medical assessment.

Larrea Tridentata Leaf extract functions as an exogenous antigen. In sensitized individuals, the primary molecular mechanism involves the cross-linking of IgE antibodies bound to the high-affinity FceRI receptors on mast cells and basophils. This cross-linking initiates a signal transduction cascade involving tyrosine kinases (such as Syk), leading to the release of pre-formed mediators (histamine, proteases) and the de novo synthesis of lipid mediators (leukotriene C4) and cytokines (IL-4, IL-5).

In immunotherapy, the extract induces a state of immunological tolerance. This involves the expansion of Regulatory T-cells (Tregs) that produce IL-10 and TGF-beta, which suppress Th2-mediated allergic inflammation and promote the production of IgG4 blocking antibodies. These IgG4 antibodies compete with IgE for allergen binding, preventing the activation of mast cells.

• Onset of Action: For skin testing, the reaction begins within 5 minutes and peaks at 15-20 minutes.
• Duration of Effect: The diagnostic wheal usually fades within 1-2 hours. The desensitizing effect of immunotherapy can last for several years after a full course of treatment is completed.
• Tolerance: Immunological tolerance is the goal of therapy, though 'tachyphylaxis' (rapidly diminishing response) is not typically seen with these extracts.

| Parameter | Value |

|---|---|

| Bioavailability | Low (Subcutaneous) |

| Protein Binding | N/A (Biological Extract) |

| Half-life | Variable (Proteins degraded locally) |

| Tmax | 15-20 minutes (Skin Test) |

| Metabolism | Proteolytic degradation |

| Excretion | Renal/Biliary (Metabolites) |

Larrea Tridentata Leaf contains a variety of bioactive compounds, most notably Nordihydroguaiaretic acid (NDGA), a potent antioxidant lignan. It also contains flavonoids (kaempferol, quercetin), volatile oils, and various resins. The molecular weight of the allergenic proteins typically ranges from 10 to 70 kDa. The extract is soluble in aqueous buffers and glycerol-based solutions.

Larrea Tridentata Leaf is classified as a Non-Standardized Plant Allergenic Extract. It is related to other desert plant extracts such as Sagebrush (Artemisia) and Mesquite (Prosopis).